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Ina Tesseur1,2 and Bart De Strooper1,2*Abstract
With 27 million people affected by Alzheimer’s disease
(AD), any proposal of a novel avenue for drug
development is hot news. When Cramer and
colleagues proposed last year that they could tackle
AD pathology in an AD mouse model with
bexarotene, a drug already in use in the clinic for
other diseases, the news was covered worldwide by
the popular press. Apolipoprotein E4 is the strongest
genetic risk factor for AD and bexarotene appeared to
exert spectacular effects on AD pathology when
tested in APP/PS1 transgenic mice. One year later the
slumbering discussion on the use of bexarotene in AD
exploded in a flurry of papers. Four papers question
the initial optimistic claims, while two others can only
partially support the original work. We summarize here
the available data and try to make sense out of the
controversy. The major question is what we can learn
from the experiments and what these studies imply
for the further development of bexarotene in the
clinic.genes involved in lipid metabolism through obligatoryApolipoprotein E4 (apoE4) is the most important genetic
risk factor for sporadic Alzheimer’s disease (AD) and
therefore an interesting drug target per se. Despite nu-
merous studies trying to address by which mechanism
apoE4 affects the risk for AD, a definitive answer has
not yet emerged. Both the ideas that apoE4 accelerates
and fails to protect against disease have been proposed
[1-3]. These opposite views have important implications
when devising therapeutic strategies for AD. If apoE4 ac-
celerates the disease, then inhibition of apoE4, or the
toxic pathways in which it plays a role, would be re-
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© 2013 BioMed Central Ltd.inhibiting the cleavage of apoE4 into toxic fragments or
blocking apoE4’s effects on amyloid beta (Aβ)
oligomerization [2,3]. If apoE4 fails to protect against
AD, however, then potentiation of the function of wild-
type apoE would be desirable - for instance, by generat-
ing apoE3 mimetics, which could improve the brain
clearance of Aβ that may be affected in APOE4 carriers
[1,3].
The paper by Cramer and colleagues [4] fitted nicely
into the second strategy and showed that upregulation
of apoE and apoE-related pathways could improve amyl-
oid plaque accumulation and behavior in a mouse model
of AD. Moreover, it demonstrated that this was possible
by administering the drug bexarotene, which was already
approved by the US Food and Drug Administration
(FDA) for use in humans [5]. The excitement that this
possibility could rapidly become tested in real, sporadic
AD patients propelled the publication into the popular
press.
Bexarotene is a retinoid X receptor (RXR) agonist that
induces transcription of the ATP-binding cassette trans-
porter gene A1 (ABCA1), as well as apoE and other
heterodimerization of RXR with liver X receptor and
peroxisome proliferator-activated receptor-γ. As a result,
bexarotene induces accumulation of triglycerides in vivo,
which can result in liver steatosis and hypertriglyc-
eridemia [6]. ApoE and ABCA1 are expressed in the
central nervous system and in the periphery and meas-
uring their expression should give a good indication of
target engagement by bexarotene in both the central
nervous system and the periphery.
Given the spectacular results of Cramer and colleagues
[4], it is not surprising that many research groups world-
wide attempted to replicate the original study. The data
are summarized in Table 1. The major claim of the ori-
ginal study was a rapid clearance of Aβ deposits from
the brains of AD model mice [4]. This claim could not
be confirmed in five independent follow-up studies
[7-11], despite target engagement. Interestingly, and in
Table 1 Overview of drug formulation and experimental outcomes of Alzheimer’s disease model mice treated with
Bexarotene
Experimental claims
Research
group
Drug
formulation
Duration
of
treatment
Target
engagement
(ApoE/
ABCA1)
Decrease of
soluble Aβ
Clearance of
deposited Aβ/
plaques
Behavioral
improvements
In vivo
microglia
activation
Mechanism-
based
toxicity
Cramer et al. [4] Bexarotene/
Targretin in
DMSO or
micronized in
water
3 to
14 days
and
3 months
Increase Decrease of
Aβ40 or Aβ42
>25%
Repeated dosing of
3 to 14 days
decreases Aβ
deposits by 30 to
75%; 3-month
treatment had no
effects
Improved
context-
dependent fear
memory.
Improved spatial
memory.
Improved social
behavior
Unclear
whether
different
from
control
NR
Price et al. [9] Bexarotene in
solutol:ethanol:
water
(15:10:75)
3 to
7 days
Increase No effect No effect NR NR Increased liver
weight
Fitz et al. [11] Targretin in
glycerol
15 days Increase Decrease of ISF
Aβ40 and
Aβ42 by 23 to
26%; no effect
on extracted
soluble Aβ
No effect Improved spatial
memory.
Improved long-
term memory
NR NR
Veeraraghavalu
et al. [7]
Targretin in
DMSO:ethanol:
sunflower oil
(6.6%:4%:89.6%)
7 days Increase Small effects No effect NR No effect NR
Tesseur et al.
[8]
Bexarotene in
Captisol and
HP-β-CD/
Tween
19 days Increase No effect No effect Unclear effect on
social recognition
memory and fear
memory
NR. Loss of body
weight,
irritation and
breathing
problems,
increased
grooming
LaClair et al.
[10]
Bexarotene in
DMSO or corn
oil
3 to
14 days
Increase NR No effect No effect on
context- or
conditioned
stimulus-
dependent fear
memory
No effect NR
Ulrich et al. [12] Targretin in
water
36 hours Increase Decrease of ISF
Aβ40 by 45%
NR NR NR NR
Aβ, amyloid beta; ApoE, apolipoprotein E; DMSO, dimethyl sulfoxide; HP-β-CD, 2-hydroxypropyl-β-cyclodextrin; ISF, interstitial fluid; NR, not reported.
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leagues reported that, after chronic daily bexarotene
treatment for 3 months, they could not find a decrease
in Aβ deposits, despite reduced soluble Aβ levels and
target engagement [4]. This result is puzzling compared
to the rest of their results and no clear explanation for
this discrepancy is given. The other claims of the publi-
cation were, optimistically speaking, confirmed by some
groups and not by others. For instance, three groups
found lowering of soluble Aβ levels in interstitial fluid
[11,12] or in brain extracts [7], whereas three groups
found no effects [8,9,11]. From Table 1 it becomes clear
that the formulation of bexarotene might be very critical
in this regard. The groups who observed an effect usedTargretin for their mice. Targretin is the commercial for-
mulation of bexarotene and contains a lot of additional
‘stuff ’ (see detailed component list in [13]). This raises
the question of whether those additional components
could affect the results, especially since the bexarotene
formulations used by the other groups resulted in effi-
cient brain exposure as well, precluding the lack of tar-
get engagement as an explanation for this discrepancy.
The original publication by Cramer and colleagues [4]
mentioned the use of Targretin in some experiments
and of bexarotene powder (in water or DMSO) in other
experiments, explaining some of the confusion in the
follow-up studies. The authors [14] indicated afterwards
that they actually used Targretin for their dosing studies
Tesseur and De Strooper Alzheimer's Research & Therapy 2013, 5:54 Page 3 of 4
http://alzres.com/content/5/6/54[4] but it remains to be fully clarified what was exactly
used in the different experiments of the original work
[4].
The behavioral data analyzing the effects of bexarotene
on cognition and memory, which are crucial for the
clinic, are the most difficult and most controversial to
interpret. Cramer and colleagues [4] claimed that
bexarotene significantly improved spatial and fear mem-
ory in their mice. Improvement in spatial memory upon
bexarotene treatment was reproduced in one follow-up
study [11], but improvement of fear memory could not
be reproduced [10] or was reported to be inconclusive in
a third study [8]. The latter study, although inconclusive,
is quite informative from another perspective. Indeed,
these authors reported a series of confounding effects in
the mice treated with the drug - that is, severe loss of
total body weight, breathing problems, and increased
grooming - indicating that the mice felt rather uncom-
fortable and might even suffer from the treatment [8].
Although the authors of the Cramer and colleagues’
study interpreted the behavioral data of the latter study
in their response-comment as confirmative of their ori-
ginal data [14], the authors of the latter study were
much less positive and indicated that the animals might
have been too sick to allow any confirmative conclusions
[8]. In addition to these side effects, Price and colleagues
[9] reported evidence that bexarotene significantly in-
creased liver weight in treated mice, indicating liver
steatosis.
FDA files report that bexarotene induces severe
upregulation of triglyceride and total cholesterol levels
in many patients, and high-density lipoprotein choles-
terol is lowered in 25% of treated patients [5]. As the
dyslipidemia is reversible after stopping the treatment,
this may not pose major issues when treating cancer pa-
tients for a limited time. However, AD patients at risk
might need treatment for many years, and in such cases
the dyslipidemia would become chronic and could ser-
iously compromise cardiovascular health.
Finally, the original publication of Cramer and col-
leagues [4] claimed a significant upregulation of micro-
glial activation in bexarotene-treated animals. However,
some control stainings and quantifications were lacking
in the manuscript, making it difficult to ascertain how
definitive these observations were. Indeed, two inde-
pendent follow-up studies did not see effects on micro-
glia activation [7,10].
Conclusion
Collectively, the above summarized data neither support
nor contradict the hypothesis that apoE4 fails to protect
against AD and the question is still open. It is clear that
the original data published by Cramer and colleagues [4]
were interpreted with a lot of optimism, which isunderstandable given the huge unmet needs in the field.
Given the central role of apoE4 in the risk for AD, the
proposed approach remains potentially interesting. For
the time being, however, we strongly suggest that re-
searchers and clinicians interested in this work perform
their own additional preclinical validation before starting
clinical trials with bexarotene in humans. In addition,
given the reported side effects and possible risks, ‘off-
counter’ use of Targretin by desperate AD patients
should be tempered until all the raised issues have been
sufficiently clarified.
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